A Phase 2 Randomized, Double-blind, Placebo-controlled Trial of Ambroxol as a Disease-modifying Treatment for Parkinson's Disease Dementia

被引：0
|
作者：
Pasternak, S.
Silveira, C.
Coleman, K.
Garcia, R.
Wells, J.
Borrie, M.
MacDonald, P.
Bartha, R.
Jenkins, M.
Morrow, S.
Mendonca, D.
Zou, G.
Finger, E.
Rupar, T.
Tirona, R.
Jog, M.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
106
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [1] Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
    Silveira, C. R. A.
    MacKinley, J.
    Coleman, K.
    Li, Z.
    Finger, E.
    Bartha, R.
    Morrow, S. A.
    Wells, J.
    Borrie, M.
    Tirona, R. G.
    Rupar, C. A.
    Zou, G.
    Hegele, R. A.
    Mahuran, D.
    MacDonald, P.
    Jenkins, M. E.
    Jog, M.
    Pasternak, S. H.
    BMC NEUROLOGY, 2019, 19 (1)
  • [2] Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
    C. R. A. Silveira
    J. MacKinley
    K. Coleman
    Z. Li
    E. Finger
    R. Bartha
    S. A. Morrow
    J. Wells
    M. Borrie
    R. G. Tirona
    C. A. Rupar
    G. Zou
    R. A. Hegele
    D. Mahuran
    P. MacDonald
    M. E. Jenkins
    M. Jog
    S. H. Pasternak
    BMC Neurology, 19
  • [3] A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson's disease Dementia.
    Pasternak, S. H.
    Silviera, C.
    Coleman, K.
    Finger, E.
    Wells, J.
    Borrie, M.
    Morrow, S.
    Zou, G.
    Bartha, R.
    Macdonald, P.
    Jenkins, M. E.
    Jog, M.
    Tirona, R.
    Rupar, C. A.
    MOVEMENT DISORDERS, 2021, 36 : S189 - S190
  • [4] A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease
    Marrinan, Sarah L.
    Otiker, Tal
    Vasist, Lakshmi S.
    Gibson, Rachel A.
    Sarai, Bhopinder K.
    Barton, Matthew E.
    Richards, Duncan B.
    Hellstrom, Per M.
    Nyholm, Dag
    Dukes, George E.
    Burn, David J.
    MOVEMENT DISORDERS, 2018, 33 (02) : 329 - 332
  • [5] A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
    Richard, I. H.
    McDermott, M. P.
    Kurlan, R.
    Lyness, J. M.
    Como, P. G.
    Pearson, N.
    Factor, S. A.
    Juncos, J.
    Ramos, C. Serrano
    Brodsky, M.
    Manning, C.
    Marsh, L.
    Shulman, L.
    Fernandez, H. H.
    Black, K. J.
    Panisset, M.
    Christine, C. W.
    Jiang, W.
    Singer, C.
    Horn, S.
    Pfeiffer, R.
    Rottenberg, D.
    Slevin, J.
    Elmer, L.
    Press, D.
    Hyson, H. C.
    McDonald, W.
    NEUROLOGY, 2012, 78 (16) : 1229 - 1236
  • [6] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353
  • [7] A randomized, double-blind, placebo-controlled trial of hydrogen water in Parkinson's disease
    Yoritaka, A.
    Takanashi, M.
    Hirayama, M.
    Ohta, S.
    Hattori, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 311 - 311
  • [8] A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson's disease
    Chong, K. K.
    Lim, S. Y.
    Manap, M. A. A. A.
    Lim, J. L.
    Low, S. C.
    Mahadeva, S. K.
    Tan, A. H.
    MOVEMENT DISORDERS, 2018, 33 : S194 - S194
  • [9] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [10] Zishenpingchan granules for the treatment of Parkinson's disease:a randomized,double-blind,placebo-controlled clinical trial
    Qing Ye
    Xiao-Lei Yuan
    Can-Xing Yuan
    Hong-Zhi Zhang
    Xu-Ming Yang
    Neural Regeneration Research, 2018, (07) : 1269 - 1275
12345